Skip to main content
Terug
MEPDF logo

MediPal Holdings Corporation

Datakwaliteit: 100%
Overbought
MEPDF
OTC Healthcare Medical - Distribution
€ 19,00
€ 0,00 (0,00%)
Marktkapitalisatie: 3,89B
Ook genoteerd als MAHLY OTC
Dagbereik
€ 19,00 € 19,00
52-Weeksbereik
€ 14,75 € 19,00
Volume
200
50D / 200D Gem.
€ 18,50 / € 16,78
Vorige Slotkoers
€ 19,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 6,6 3,7
Net Margin % 1,1 3,8
Rev Growth 5Y % 3,4 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 3,40% annually over 5 years — modest growth
Debt/Equity of 0,00 — conservative balance sheet
Generating 48,13B in free cash flow
P/E of 0,10 — trading at a low valuation
Cash machine — converts 119,49% of earnings into free cash flow
Capital efficient — spends only 0,34% of revenue on capex

Groei

Revenue Growth (5Y)
3,40%
Revenue (1Y)3,16%
Earnings (1Y)-2,88%
FCF Growth (3Y)326,81%

Kwaliteit

Return on Equity
6,60%
ROIC6,73%
Net Margin1,10%
Op. Margin1,51%

Veiligheid

Debt / Equity
0,00
Current Ratio1,27
Interest Coverage7944,14

Waardering

P/E Ratio
0,10
P/B Ratio0,01
EV/EBITDA-4,63
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,16% Revenue Growth (3Y) 4,53%
Earnings Growth (1Y) -2,88% Earnings Growth (3Y) 1,88%
Revenue Growth (5Y) 3,40% Earnings Growth (5Y) 13,91%
Profitability
Revenue (TTM) 3,67T Net Income (TTM) 40,28B
ROE 6,60% ROA 2,21%
Gross Margin 6,97% Operating Margin 1,51%
Net Margin 1,10% Free Cash Flow (TTM) 48,13B
ROIC 6,73% FCF Growth (3Y) 326,81%
Safety
Debt / Equity 0,00 Current Ratio 1,27
Interest Coverage 7944,14 Dividend Yield 0,02%
Valuation
P/E Ratio 0,10 P/B Ratio 0,01
P/S Ratio 0,00 PEG Ratio -9,71
EV/EBITDA -4,63 Dividend Yield 0,02%
Market Cap 3,89B Enterprise Value -257,52B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,67T 3,56T 3,36T 3,29T 3,21T
Net Income 40,28B 41,47B 38,81B 29,42B 23,93B
EPS (Diluted) 193,20 195,83 179,12 131,41 106,80
Gross Profit 255,76B 246,66B 224,31B 217,45B 214,26B
Operating Income 55,61B 47,33B 48,97B 45,62B 38,58B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,82T 1,80T 1,70T 1,71T 1,68T
Total Liabilities 1,07T 1,06T 1,02T 1,06T 1,04T
Shareholders' Equity 619,56B 600,35B 561,36B 530,30B 523,01B
Total Debt 0,0 1,46B 7,38B 30,08B 30,58B
Cash & Equivalents 261,41B 230,15B 195,03B 243,15B 222,75B
Current Assets 1,28T 1,24T 1,18T 1,21T 1,17T
Current Liabilities 1,01T 1,01T 971,52B 1,01T 952,84B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#580 of 820
34
Value Defensive Investing (Benjamin Graham)
#691 of 708
1

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026